The Government of Mexico announced the signing of a purchase agreement for Pfizer’s oral antiviral therapy against Covid-19, called Paxlovid.
The contract completes the acquisition of 300,000 oral treatments which have already begun their arrival in the country.
Pfizer’s antiviral treatment, focused on being administered to people who have the disease caused by the SARS-CoV-2 virus and who are at high risk of developing complications, was approved by the Federal Commission for the Protection against Sanitary Risks ( Cofepris ) last January 2022, being the first health regulatory agency in Latin America to approve it, and the second country in the region to be supplied.
The treatment includes nirmatrelvir, a protease inhibitor that was specifically designed to block the activity of SARS-CoV-2 protease 3CL, an enzyme that the coronavirus needs to replicate.
Data show that this treatment reduces the risk of hospitalization or death by 89% when started within three days of symptom onset and by 88% when started within the fourth to fifth day of symptom onset, compared to a placebo test group.
Constanza Losada, president and CEO of Pfizer Mexico, said that this agreement helps them continue working hand in hand with the Government of Mexico to address this public health crisis.
“The fight and commitment to end the effects of the pandemic is everyone’s task and this is reflected in the agreement we have signed to continue seeking the well-being of people,” he said.
To date, Pfizer has supplied more than 26.2 million oral treatments against Covid-19 to 41 countries.
Co-administration with a low dose of ritonavir helps slow down the metabolism or breakdown of nirmatrelvir so that it remains active in the body longer at higher concentrations to help fight the virus.
Pfizer noted that nirmatrelvir showed no evidence of mutagenic interactions with DNA .
Nirmatrelvir has shown consistent antiviral activity in vitro against former and current variants such as Alpha, Beta, Delta, Gamma, Lambda, Mu, and omicron.
It is a drug produced by the pharmaceutical company Pfizer and recommended by the World Health Organization (WHO) to treat the early stages of the Covid-19 disease in patients at risk of hospitalization, such as the elderly, immunosuppressed, or unvaccinated.
Paxlovid actually consists of two drugs, nirmatrelvir and ritonavir. The former is an antiviral and the latter is a pharmacokinetic enhancer.
Paxlovid is only recommended for adults and adolescents 12 years of age and older.
The oral antiretroviral drug from the Pfizer laboratory is administered in the early stages of the disease when serious symptoms have not yet developed. One tablet is taken orally every 24 hours for five days. According to the WHO, it is indicated for patients “with non-severe forms of Covid-19 who are at high risk of evolving into severe forms of the disease and of being hospitalized, such as unvaccinated, elderly or immunosuppressed patients.”
One of the biggest questions that experts raised about the drug is the “rebound” effect that was seen in some patients after taking it. Fauci himself experienced this phenomenon, when after three days of negative rapid tests for Covid-19, he contracted the virus again, manifesting some mild symptoms such as low-grade fever, sore throat, and body aches.
Fauci, however, persisted in his defense of Paxlovid, arguing that the drug served “its original purpose” which was to prevent his hospitalization. “It’s not meant to prevent rebounds. It is meant to prevent you from being hospitalized. I’m 81 years old, I was at risk of hospitalization and I wasn’t even sick enough to be hospitalized,” Fauci told reporters.
Early this week, US President Joe Biden also experienced a COVID-19 rebound after being treated with the drug and testing negative.
Subscribe here for just .08 cents per day to read subscriber content, join the PVDN newsletter, and browse with site ad-free. Support local news.
Trending news on PVDN
- Puerto Vallarta or Cancun? Security issues in Acapulco and Cancún could attract tourists to Puerto Vallarta as a safer alternative The unfortunate situation of violence and insecurity that exists in tourist destinations such as Acapulco or Cancun, where executions or disputes between taxi drivers and Uber, respectively, are taking place, could attract more tourism to Puerto Vallarta, answering the question: Puerto Vallarta or Cancun?
- Crocodile captured in Puerto Vallarta at Parque Lineal Elements of the Municipal Government’s Environment Department captured an adult crocodile approximately 2.63 meters long, in Linear Park, near the Ex Haciendas del Pitillal, this Wednesday. The specimen is marked with the number 530 and was relocated to the El Salado estuary. This happens in the commemoration of the Day of the Biologist, professionals who…
- Puerto Vallarta Malecón will be repaired due to damage caused by high waves In a regular session of the Tourism and Economic Development Commission in cooperation with the Environment and Public Services Commissions, the opinion derived from a building agreement initiative was approved this Wednesday to carry out the repair of the Puerto Vallarta Malecón, due to the damage it suffered as a result of the high waves.…
- Puerto Vallarta recognizes heroic action of policeman who saved tourist from drowning Officer Alejandro Abarca Álvarez, a tourist area policeman, who on January 15 saved the life of a tourist from Guadalajara after being swept away by ocean currents, was recognized for his heroic actions. The rescue was registered at around 5:00 pm at Camarones Beach next to the Rosita Hotel and according to the report of…
- Mexico will stop producing the 20 peso bill and replace it with a coin Just what everyone wants! More change in their pocket. The Bank of Mexico (Banxico) announced that in 2025 the 20-peso bill will cease to circulate, to be replaced by coins, due to its practicality, and will cease to be produced this year 2023. “The banknotes and coins in the withdrawal process still retain their liberating…